Trial Profile

Precision Promise Platform Trial for Metastatic Pancreatic Cancer

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 10 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canakinumab (Primary) ; Nadunolimab (Primary) ; Pamrevlumab (Primary) ; Pelareorep (Primary) ; Racemetyrosine (Primary) ; Spartalizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Methoxsalen; Oxaliplatin; Paclitaxel; Phenytoin; Sirolimus
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Registrational; Therapeutic Use
Acronyms PanCAN-Precision-PromiseSM; Precision Promise

Most Recent Events

06 Apr 2025 Status changed from active, no longer recruiting to completed.
30 Jul 2024 Results published in a FibroGen media release.
30 Jul 2024 According to a FibroGen media release,Primary endpoint (Overall Survival) has not been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com